{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T03:30:33Z","timestamp":1775705433363,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology","award":["15K09675 and 18K07894"],"award-info":[{"award-number":["15K09675 and 18K07894"]}]},{"name":"The Japan Foundation for Pediatric Research","award":["year 2015"],"award-info":[{"award-number":["year 2015"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Human cytomegalovirus (HCMV) causes asymptomatic infections, but also causes congenital infections when women were infected with HCMV during pregnancy, and life-threatening diseases in immunocompromised patients. To better understand the mechanism of the neutralization activity against HCMV, the association of HCMV NT antibody titers was assessed with the antibody titers against each glycoprotein complex (gc) of HCMV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Sera collected from 78 healthy adult volunteers were used. HCMV Merlin strain and HCMV clinical isolate strain 1612 were used in the NT assay with the plaque reduction assay, in which both the MRC-5 fibroblasts cells and the RPE-1 epithelial cells were used. Glycoprotein complex of gB, gH\/gL complexes (gH\/gL\/gO and gH\/gL\/UL128\u2013131A [PC]) and gM\/gN were selected as target glycoproteins. 293FT cells expressed with gB, gM\/gN, gH\/gL\/gO, or PC, were prepared and used for the measurement of the antibody titers against each gc in an indirect immunofluorescence assay (IIFA). The correlation between the IIFA titers to each gc and the HCMV-NT titers was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were no significant correlations between gB-specific IIFA titers and the HCMV-NT titers in epithelial cells or between gM\/gN complex-specific IIFA titers and the HCMV-NT titers. On the other hand, there was a statistically significant positive correlation between the IIFA titers to gH\/gL complexes and HCMV-NT titers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The data suggest that the gH\/gL complexes might be the major target to induce NT activity against HCMV.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12985-020-01390-2","type":"journal-article","created":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T08:06:34Z","timestamp":1596441994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Association of human cytomegalovirus (HCMV) neutralizing antibodies with antibodies to the HCMV glycoprotein complexes"],"prefix":"10.1186","volume":"17","author":[{"given":"Miho","family":"Shibamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Souichi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phu Hoang Anh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikaru","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shizuko","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuetsu","family":"Fukushi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Mizuguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5458-7298","authenticated-orcid":false,"given":"Masayuki","family":"Saijo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,3]]},"reference":[{"key":"1390_CR1","first-page":"417","volume":"325","author":"W Britt","year":"2008","unstructured":"Britt W. Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. Curr Top Microbiol Immunol. 2008;325:417\u201370.","journal-title":"Curr Top Microbiol Immunol"},{"key":"1390_CR2","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.jpeds.2005.01.059","volume":"146","author":"SB Boppana","year":"2005","unstructured":"Boppana SB, Fowler KB, Pass RF, Rivera LB, Bradford RD, Lakeman FD, et al. Congenital cytomegalovirus infection: association between virus burden in infancy and hearing loss. J Pediatr. 2005;146:817\u201323.","journal-title":"J Pediatr"},{"key":"1390_CR3","first-page":"1960","volume-title":"Chapter 62 Cytomegaloviruses","author":"S Edward","year":"2013","unstructured":"Edward S, Mocarski J, Shenk T, Griffiths PD, Pass RF. Fields Virology. In: Knipe DM, Howley PM, editors. Chapter 62 Cytomegaloviruses. 6th ed. Philadelphia: Walters Kluwer; 2013. p. 1960\u20132014.","edition":"6"},{"key":"1390_CR4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/infdis\/165.2.381","volume":"165","author":"GS Marshall","year":"1992","unstructured":"Marshall GS, Rabalais GP, Stout GG, Waldeyer SL. Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. J Infect Dis. 1992;165:381\u20134.","journal-title":"J Infect Dis"},{"key":"1390_CR5","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1128\/JVI.80.9.4591-4600.2006","volume":"80","author":"M Shimamura","year":"2006","unstructured":"Shimamura M, Mach M, Britt WJ. Human cytomegalovirus infection elicits a glycoprotein M (gM)\/gN-specific virus-neutralizing antibody response. J Virol. 2006;80:4591\u2013600.","journal-title":"J Virol"},{"key":"1390_CR6","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1128\/JVI.01809-09","volume":"84","author":"A Macagno","year":"2010","unstructured":"Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, Revello MG, et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH\/gL\/UL128-131A complex. J Virol. 2010;84:1005\u201313.","journal-title":"J Virol"},{"issue":"3","key":"1390_CR7","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00430-015-0388-z","volume":"204","author":"S Plotkin","year":"2015","unstructured":"Plotkin S. The history of vaccination against cytomegalovirus. Med Microbiol Immunol. 2015;204(3):247\u201354.","journal-title":"Med Microbiol Immunol"},{"issue":"Suppl 4","key":"1390_CR8","doi-asserted-by":"crossref","first-page":"S196","DOI":"10.1093\/cid\/cit587","volume":"57","author":"MA McVoy","year":"2013","unstructured":"McVoy MA. Cytomegalovirus vaccines. Clin Infect Dis. 2013;57(Suppl 4):S196\u20139.","journal-title":"Clin Infect Dis"},{"key":"1390_CR9","first-page":"361","volume":"325","author":"MR Schleiss","year":"2008","unstructured":"Schleiss MR. Cytomegalovirus vaccine development. Curr Top Microbiol Immunol. 2008;325:361\u201382.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"Suppl 5","key":"1390_CR10","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1111\/1469-0691.12449","volume":"20","author":"F Rieder","year":"2014","unstructured":"Rieder F, Steininger C. Cytomegalovirus vaccine: phase II clinical trial results. Clin Microbiol Infect. 2014;20(Suppl 5):S95\u2013102.","journal-title":"Clin Microbiol Infect"},{"key":"1390_CR11","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/j.vaccine.2014.03.057","volume":"32","author":"TM Fu","year":"2014","unstructured":"Fu TM, An Z, Wang D. Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease. Vaccine. 2014;32:2525\u201333.","journal-title":"Vaccine"},{"key":"1390_CR12","doi-asserted-by":"crossref","first-page":"10023","DOI":"10.1128\/JVI.78.18.10023-10033.2004","volume":"78","author":"G Hahn","year":"2004","unstructured":"Hahn G, Revello MG, Patrone M, Percivalle E, Campanini G, Sarasini A, et al. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol. 2004;78:10023\u201333.","journal-title":"J Virol"},{"key":"1390_CR13","doi-asserted-by":"crossref","first-page":"10330","DOI":"10.1128\/JVI.79.16.10330-10338.2005","volume":"79","author":"D Wang","year":"2005","unstructured":"Wang D, Shenk T. Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J Virol. 2005;79:10330\u20138.","journal-title":"J Virol"},{"key":"1390_CR14","doi-asserted-by":"crossref","first-page":"18153","DOI":"10.1073\/pnas.0509201102","volume":"102","author":"D Wang","year":"2005","unstructured":"Wang D, Shenk T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci U S A. 2005;102:18153\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1390_CR15","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1016\/j.vaccine.2008.07.092","volume":"26","author":"X Cui","year":"2008","unstructured":"Cui X, Meza BP, Adler SP, McVoy MA. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine. 2008;26:5760\u20136.","journal-title":"Vaccine"},{"key":"1390_CR16","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1099\/vir.0.83523-0","volume":"89","author":"G Gerna","year":"2008","unstructured":"Gerna G, Sarasini A, Patrone M. Percivalle E1, Fiorina L, Campanini G, et al. human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial\/epithelial cells, but not fibroblasts, early during primary infection. J Gen Virol. 2008;89:853\u201365.","journal-title":"J Gen Virol"},{"key":"1390_CR17","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1128\/JVI.00467-12","volume":"86","author":"AE Fouts","year":"2012","unstructured":"Fouts AE, Chan P, Stephan JP, Vandlen R, Feierbach B. Antibodies against the gH\/gL\/UL128\/UL130\/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J Virol. 2012;86:7444\u20137.","journal-title":"J Virol"},{"key":"1390_CR18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059863","volume":"8","author":"D Lilleri","year":"2013","unstructured":"Lilleri D, Kabanova A, Revello MG, Percivalle E, Sarasini A, Genini E, et al. Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH\/gL\/pUL128-130-131 complex during primary infection. PLoS One. 2013;8:e59863.","journal-title":"PLoS One"},{"key":"1390_CR19","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1128\/MMBR.00018-16","volume":"80","author":"TJ Gardner","year":"2016","unstructured":"Gardner TJ, Tortorella D. Virion glycoprotein-mediated immune evasion by human Cytomegalovirus: a sticky virus makes a slick getaway. Microbiol Mol Biol Rev. 2016;80:663\u201377.","journal-title":"Microbiol Mol Biol Rev"},{"issue":"Suppl 4","key":"1390_CR20","doi-asserted-by":"crossref","first-page":"S174","DOI":"10.1093\/cid\/cit583","volume":"57","author":"L Pereira","year":"2013","unstructured":"Pereira L, Petitt M, Tabata T. Cytomegalovirus infection and antibody protection of the developing placenta. Clin Infect Dis. 2013;57(Suppl 4):S174\u20137.","journal-title":"Clin Infect Dis"},{"key":"1390_CR21","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2353\/ajpath.2006.050482","volume":"168","author":"E Maidji","year":"2006","unstructured":"Maidji E, McDonagh S, Genbacev O, Tabata T, Pereira L. Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal fc receptor-mediated transcytosis. Am J Pathol. 2006;168:1210\u201326.","journal-title":"Am J Pathol"},{"key":"1390_CR22","doi-asserted-by":"crossref","first-page":"10489","DOI":"10.1128\/JVI.01546-13","volume":"87","author":"I Murrell","year":"2013","unstructured":"Murrell I, Tomasec P, Wilkie GS, Dargan DJ, Davison AJ, Stanton RJ. Impact of sequence variation in the UL128 locus on production of human cytomegalovirus in fibroblast and epithelial cells. J Virol. 2013;87:10489\u2013500.","journal-title":"J Virol"},{"key":"1390_CR23","doi-asserted-by":"crossref","first-page":"9680","DOI":"10.1128\/JVI.01167-13","volume":"87","author":"M Zhou","year":"2013","unstructured":"Zhou M, Yu Q, Wechsler A, Ryckman BJ. Comparative analysis of gO isoforms reveals that strains of human cytomegalovirus differ in the ratio of gH\/gL\/gO and gH\/gL\/UL128-131 in the virion envelope. J Virol. 2013;87:9680\u201390.","journal-title":"J Virol"},{"key":"1390_CR24","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1172\/JCI42955","volume":"120","author":"RJ Stanton","year":"2010","unstructured":"Stanton RJ, Baluchova K, Dargan DJ, Cunningham C, Sheehy O, Seirafian S, et al. Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication. J Clin Invest. 2010;120:3191\u2013208.","journal-title":"J Clin Invest"},{"key":"1390_CR25","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jcv.2013.12.013","volume":"59","author":"K Taniguchi","year":"2014","unstructured":"Taniguchi K, Watanabe N, Sato A, Jwa SC, Suzuki T, Yamanobe Y, et al. Changes in cytomegalovirus seroprevalence in pregnant Japanese women-a 10-year single center study. J Clin Virol. 2014;59:192\u20134.","journal-title":"J Clin Virol"},{"key":"1390_CR26","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.ajic.2015.06.026","volume":"43","author":"D Shigemi","year":"2015","unstructured":"Shigemi D, Yamaguchi S, Otsuka T, Kamoi S, Takeshita T. Seroprevalence of cytomegalovirus IgG antibodies among pregnant women in Japan from 2009-2014. Am J Infect Control. 2015;43:1218\u201321.","journal-title":"Am J Infect Control"},{"key":"1390_CR27","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/jmv.1890200209","volume":"20","author":"H Schmitz","year":"1986","unstructured":"Schmitz H, Essuman S. Comparison of the neutralizing and ELISA antibody titres to human cytomegalovirus (HCMV) in human sera and in gamma globulin preparations. J Med Virol. 1986;20:177\u201382.","journal-title":"J Med Virol"},{"key":"1390_CR28","doi-asserted-by":"crossref","first-page":"9075","DOI":"10.1016\/j.vaccine.2011.09.056","volume":"29","author":"D Wang","year":"2011","unstructured":"Wang D, Li F, Freed DC, Finnefrock AC, Tang A, Grimes SN, et al. Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection. Vaccine. 2011;29:9075\u201380.","journal-title":"Vaccine."},{"key":"1390_CR29","first-page":"289","volume":"24","author":"G Leogrande","year":"1992","unstructured":"Leogrande G, Merchionne F, Lazzarotto T, Landini MP. Large-scale testing of human serum to determine cytomegalovirus neutralising antibody. J Inf Secur. 1992;24:289\u201399.","journal-title":"J Inf Secur"},{"key":"1390_CR30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005230","volume":"11","author":"C Ciferri","year":"2015","unstructured":"Ciferri C, Chandramouli S, Leitner A, Donnarumma D, Cianfrocco MA, Gerrein R, et al. Antigenic characterization of the HCMV gH\/gL\/gO and pentamer cell entry complexes reveals binding sites for potently neutralizing human antibodies. PLoS Pathog. 2015;11:e1005230.","journal-title":"PLoS Pathog"},{"key":"1390_CR31","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1073\/pnas.1424818112","volume":"112","author":"C Ciferri","year":"2015","unstructured":"Ciferri C, Chandramouli S, Donnarumma D, Nikitin PA, Cianfrocco MA, Gerrein R, et al. Structural and biochemical studies of HCMV gH\/gL\/gO and Pentamer reveal mutually exclusive cell entry complexes. Proc Natl Acad Sci U S A. 2015;112:1767\u201372.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1390_CR32","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1128\/jvi.64.3.1079-1085.1990","volume":"64","author":"WJ Britt","year":"1990","unstructured":"Britt WJ, Vugler L, Butfiloski EJ, Stephens EB. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol. 1990;64:1079\u201385.","journal-title":"J Virol"},{"key":"1390_CR33","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/infdis\/174.2.387","volume":"174","author":"JB Wang","year":"1996","unstructured":"Wang JB, Adler SP, Hempfling S, Burke RL, Duli\u00e8ge AM, Starr SE, et al. Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines. J Infect Dis. 1996;174:387\u201392.","journal-title":"J Infect Dis"},{"key":"1390_CR34","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0264-410X(91)90187-B","volume":"9","author":"E G\u00f6ncz\u00f6l","year":"1991","unstructured":"G\u00f6ncz\u00f6l E, deTaisne C, Hirka G, Berencsi K, Lin WC, Paoletti E, et al. High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant: the importance of the gB protein in HCMV immunity. Vaccine. 1991;9:631\u20137.","journal-title":"Vaccine"},{"key":"1390_CR35","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jim.2007.02.001","volume":"322","author":"AM Abai","year":"2007","unstructured":"Abai AM, Smith LR, Wloch MK. Novel microneutralization assay for HCMV using automated data collection and analysis. J Immunol Methods. 2007;322:82\u201393.","journal-title":"J Immunol Methods"},{"key":"1390_CR36","volume":"11","author":"HG Burke","year":"2015","unstructured":"Burke HG, Heldwein EE. Crystal structure of the human cytomegalovirus glycoprotein B. PLoS Pathog. 2015;11:e1005227.","journal-title":"PLoS Pathog"},{"issue":"24","key":"1390_CR37","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1073\/pnas.1800177115","volume":"115","author":"CS Nelson","year":"2018","unstructured":"Nelson CS, Huffman T, Jenks JA, de la Rosa EC, Xie G, Vandergrift N. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions. Proc Natl Acad Sci U S A. 2018;115(24):6267\u201372.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"1390_CR38","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1073\/pnas.1800224115","volume":"115","author":"I Baraniak","year":"2018","unstructured":"Baraniak I, Kropff B, Ambrose L, McIntosh M, McLean GR, Pichon S. Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies. Proc Natl Acad Sci U S A. 2018;115(24):6273\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1390_CR39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002172","volume":"7","author":"S P\u00f6tzsch","year":"2011","unstructured":"P\u00f6tzsch S, Spindler N, Wiegers AK, Fisch T, R\u00fccker P, Sticht H, et al. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies. PLoS Pathog. 2011;7:e1002172.","journal-title":"PLoS Pathog"},{"key":"1390_CR40","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41541-017-0038-0","volume":"2","author":"F Li","year":"2017","unstructured":"Li F, Freed DC, Tang A, Rustandi RR, Troutman MC, Espeseth AS, et al. Complement enhances in vitro neutralizing potency of antibodies to human cytomegalovirus glycoprotein B (gB) and immune sera induced by gB\/MF59 vaccination. NPJ Vaccines. 2017;2:36.","journal-title":"NPJ Vaccines"},{"key":"1390_CR41","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1016\/j.vaccine.2018.07.056","volume":"36","author":"X Cui","year":"2018","unstructured":"Cui X, Cao Z, Wang S, Lee RB, Wang X, Murata H, et al. Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response. Vaccine. 2018;36:5580\u201390.","journal-title":"Vaccine"},{"key":"1390_CR42","doi-asserted-by":"crossref","first-page":"8176","DOI":"10.1038\/ncomms9176","volume":"6","author":"S Chandramouli","year":"2015","unstructured":"Chandramouli S, Ciferri C, Nikitin PA, et al. Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralizing human antibody. Nat Commun. 2015;6:8176.","journal-title":"Nat Commun"},{"key":"1390_CR43","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1016\/j.vaccine.2007.01.011","volume":"25","author":"S Shen","year":"2007","unstructured":"Shen S, Wang S, Britt WJ, Lu S. DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates. Vaccine. 2007;25:3319\u201327.","journal-title":"Vaccine"},{"key":"1390_CR44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002999","volume":"8","author":"B Kropff","year":"2012","unstructured":"Kropff B, Burkhardt C, Schott J, Nentwich J, Fisch T, Britt W, et al. Glycoprotein N of human cytomegalovirus protects the virus from neutralizing antibodies. PLoS Pathog. 2012;8:e1002999.","journal-title":"PLoS Pathog"},{"key":"1390_CR45","doi-asserted-by":"crossref","first-page":"10960","DOI":"10.1128\/JVI.78.20.10960-10966.2004","volume":"78","author":"SM Varnum","year":"2004","unstructured":"Varnum SM, Streblow DN, Monroe ME, Smith P, Auberry KJ, Pasa-Tolic L, et al. Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J Virol. 2004;78:10960\u20136.","journal-title":"J Virol"},{"key":"1390_CR46","doi-asserted-by":"crossref","first-page":"8209","DOI":"10.1073\/pnas.1404653111","volume":"111","author":"AE Fouts","year":"2014","unstructured":"Fouts AE, Comps-Agrar L, Stengel KF, Ellerman D, Schoeffler AJ, Warming S, et al. Mechanism for neutralizing activity by the anti-CMV gH\/gL monoclonal antibody MSL-109. Proc Natl Acad Sci U S A. 2014;111:8209\u201314.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1390_CR47","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1128\/JVI.02249-09","volume":"84","author":"PT Wille","year":"2010","unstructured":"Wille PT, Knoche AJ, Nelson JA, Jarvis MA, Johnson DC. A human cytomegalovirus gO-null mutant fails to incorporate gH\/gL into the virion envelope and is unable to enter fibroblasts and epithelial and endothelial cells. J Virol. 2010;84:2585\u201396.","journal-title":"J Virol"},{"key":"1390_CR48","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jcv.2011.06.018","volume":"52","author":"E Genini","year":"2011","unstructured":"Genini E, Percivalle E, Sarasini A, Revello MG, Baldanti F, Gerna G. Serum antibody response to the gH\/gL\/pUL128-131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections. J Clin Virol. 2011;52:113\u20138.","journal-title":"J Clin Virol"},{"key":"1390_CR49","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.vaccine.2011.01.079","volume":"29","author":"FM Saccoccio","year":"2011","unstructured":"Saccoccio FM, Sauer AL, Cui X, Armstrong AE, Habib e-SE, Johnson DC, et al. Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells. Vaccine. 2011;29:2705\u201311.","journal-title":"Vaccine"},{"key":"1390_CR50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004524","volume":"10","author":"F Wussow","year":"2014","unstructured":"Wussow F, Chiuppesi F, Martinez J, Campo J, Johnson E, Flechsig C, et al. Human cytomegalovirus vaccine based on the envelope gH\/gL pentamer complex. PLoS Pathog. 2014;10:e1004524.","journal-title":"PLoS Pathog"},{"key":"1390_CR51","doi-asserted-by":"crossref","first-page":"11881","DOI":"10.1128\/JVI.74.24.11881-11892.2000","volume":"74","author":"M Mach","year":"2000","unstructured":"Mach M, Kropff B, Dal Monte P, Britt W. Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73). J Virol. 2000;74:11881\u201392.","journal-title":"J Virol"},{"key":"1390_CR52","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1128\/JVI.79.4.2160-2170.2005","volume":"79","author":"M Mach","year":"2005","unstructured":"Mach M, Kropff B, Kryzaniak M, Britt W. Complex formation by glycoproteins M and N of human cytomegalovirus: structural and functional aspects. J Virol. 2005;79:2160\u201370.","journal-title":"J Virol"},{"key":"1390_CR53","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1128\/JVI.01910-07","volume":"82","author":"BJ Ryckman","year":"2008","unstructured":"Ryckman BJ, Rainish BL, Chase MC, Borton JA, Nelson JA, Jarvis MA, Johnson DC. Characterization of the human cytomegalovirus gH\/gL\/UL128-131 complex that mediates entry into epithelial and endothelial cells. J Virol. 2008;82:60\u201370.","journal-title":"J Virol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-020-01390-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-020-01390-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-020-01390-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T19:56:30Z","timestamp":1627934190000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-020-01390-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,3]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1390"],"URL":"https:\/\/doi.org\/10.1186\/s12985-020-01390-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-22591\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-22591\/v2","asserted-by":"object"}]},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,3]]},"assertion":[{"value":"20 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was carried out under the approval of the Medical Research Ethics Committee of the National Institute of Infectious Diseases (NIID) for the use of human subjects (Approval number: 797). Informed consent was obtained from all volunteer blood donors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}